Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for Obstructive Hypertrophic Cardiomyopathy
Annals of Pharmacotherapy, Ahead of Print. Objective:To assess mavacamten’s role in hypertrophic cardiomyopathy treatment.Data Sources:In addition to clinical guidelines, package inserts, and general reviews, we […]